The CDK4/6 inhibitor in HR-positive advanced breast cancer: A systematic review and meta-analysis

Medicine
Wu DingChuanjian Tu

Abstract

Recently, several high-quality clinical randomized controlled trials (RCTs) have identified that cyclin-dependent kinases (CDKs) 4/6 inhibitors obtained a great safety and efficacy, which can be consequently applied as a combination therapy with letrozole or fulvestrant for women who had advanced breast cancer and progressed while receiving endocrine therapy. In this systemic review, we performed a meta-analysis to explore whether CDK4/6 inhibitors had a significantly benefit to treating hormone receptor-positive (HR-positive)/human epidermal growth factor receptor 2 negative (HER2-negative) advanced breast cancer. The data for meta-analysis were collected from MEDLINE, EMBASE, and Cochrane Library from January 1980 to December 2017, and eventually 3182 patients from 6 RCTs were included. The result showed the CDK4/6 inhibitor group had a longer progression-free survival (PFS) (hazard ratio = 0.51; 95% confidence interval [CI], 0.46-0.57, P < .00001), a better objective response (risk rate = 1.53; 95% CI, 1.35-1.74, P < .00001), as well as a better clinical benefit response (risk rate = 1.29; 95% CI, 1.13-1.47, P = .0001). Besides, subgroup analyses of PFS according to stratification factors and other baseline characteristics c...Continue Reading

References

Aug 30, 2000·Nature·C M PerouD Botstein
Sep 22, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Angelo Di LeoMiguel Martin
Oct 5, 2010·Annual Review of Medicine·C Kent Osborne, Rachel Schiff
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Oct 4, 2011·The Journal of Clinical Investigation·Michaela J Higgins, José Baselga
Jan 12, 2012·British Journal of Cancer·A BerghoffR Bartsch
Sep 25, 2012·Nature·UNKNOWN Cancer Genome Atlas Network
May 6, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mark A Dickson
Jun 2, 2015·The New England Journal of Medicine·Nicholas C TurnerUNKNOWN PALOMA3 Study Group
Mar 30, 2016·Cancer Research·Maria Teresa Herrera-AbreuVioleta Serra
Jun 24, 2016·The Breast : Official Journal of the European Society of Mastology·G CuriglianoS A Hurvitz
Nov 3, 2016·The New England Journal of Medicine·Gabriel N HortobagyiJoyce O'Shaughnessy
Dec 14, 2016·The New England Journal of Medicine·Richard S FinnDennis J Slamon
Apr 26, 2017·Journal of Hematology & Oncology·Hanxiao XuKongming Wu
Jun 6, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George W SledgeAntonio Llombart-Cussac
Oct 3, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew P GoetzAngelo Di Leo

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02308020

Software Mentioned

Review Manager

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.